A Study of TAK-861 in People With Narcolepsy Type 1
Phase 3
Completed
NCT06505031
| Condition | Narcolepsy Type 1 |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Takeda |
|---|
| Status | Completed |
|---|
| Enrollment | 105 participants |
|---|
| Interventions | TAK-861 |
|---|
| Start date | Oct 8, 2024 |
|---|
| Completion date | Jun 4, 2025 |
|---|
| Results posted | Jul 16, 2026 |
|---|
Summary
The main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy symptoms and daily life functions; and to learn about the safety of TAK-861.
Change From Baseline to Week 12 in Mean Sleep Latency From the Maintenance of Wakefulness Test (MWT) Wake Trials
Baseline, Week 12 · minutes
| Placebo | -1.01 ± 1.529 minutes |
|---|
| Oveporexton | 19.09 ± 1.254 minutes |
|---|
| p-value | <0.001 |
|---|
| LS Mean Difference | 20.09 (95% CI 16.57–23.61) |
|---|
Change From Baseline to Week 12 in ESS Total Score
Baseline, Week 12 · score on a scale
| Placebo | -1.57 ± 0.676 score on a scale |
|---|
| Oveporexton | -11.10 ± 0.550 score on a scale |
|---|
| p-value | <0.001 |
|---|
| Least Square (LS) Mean Difference | -9.53 (95% CI -11.10–-7.97) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.